BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 38638671)

  • 1. A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis.
    Airas L; Bermel RA; Chitnis T; Hartung HP; Nakahara J; Stuve O; Williams MJ; Kieseier BC; Wiendl H
    Ther Adv Neurol Disord; 2024; 17():17562864241233041. PubMed ID: 38638671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
    Ringheim GE; Wampole M; Oberoi K
    Front Immunol; 2021; 12():662223. PubMed ID: 34803999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis.
    Steinmaurer A; Wimmer I; Berger T; Rommer PS; Sellner J
    Curr Pharm Des; 2022; 28(6):437-444. PubMed ID: 34218776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
    Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D
    Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bruton's tyrosine kinase inhibition-An emerging therapeutic strategy in immune-mediated dermatological conditions.
    Mendes-Bastos P; Brasileiro A; Kolkhir P; Frischbutter S; Scheffel J; Moñino-Romero S; Maurer M
    Allergy; 2022 Aug; 77(8):2355-2366. PubMed ID: 35175630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases.
    De Bondt M; Renders J; Struyf S; Hellings N
    Autoimmun Rev; 2024 May; 23(5):103532. PubMed ID: 38521213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bruton's Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis.
    Garg N; Padron EJ; Rammohan KW; Goodman CF
    J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Perspectives: Evidence to Date on BTK Inhibitors in the Management of Multiple Sclerosis.
    Carnero Contentti E; Correale J
    Drug Des Devel Ther; 2022; 16():3473-3490. PubMed ID: 36238195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bruton's tyrosine kinase inhibitors in the treatment of multiple sclerosis.
    Shulga O; Chabanova A; Kotsiuba O
    Postep Psychiatr Neurol; 2023 Mar; 32(1):23-30. PubMed ID: 37287740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bruton's Tyrosine Kinase Inhibition for the Treatment of Rheumatoid Arthritis.
    Arneson LC; Carroll KJ; Ruderman EM
    Immunotargets Ther; 2021; 10():333-342. PubMed ID: 34485183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bruton's Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives.
    Robak E; Robak T
    J Clin Med; 2022 May; 11(10):. PubMed ID: 35628931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Research Progress of BTK Inhibitors in the Treatment of Autoimmune Diseases.
    Lin P; Zhang D; Lin J
    Curr Top Med Chem; 2023; 23(28):2609-2620. PubMed ID: 37861005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's Tyrosine Kinase Inhibitors: A New Generation of Promising Agents for Multiple Sclerosis Therapy.
    García-Merino A
    Cells; 2021 Sep; 10(10):. PubMed ID: 34685540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting B Cells and Microglia in Multiple Sclerosis With Bruton Tyrosine Kinase Inhibitors: A Review.
    Dybowski S; Torke S; Weber MS
    JAMA Neurol; 2023 Apr; 80(4):404-414. PubMed ID: 36780171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bruton's Tyrosine Kinase Inhibition in Multiple Sclerosis.
    Schneider R; Oh J
    Curr Neurol Neurosci Rep; 2022 Nov; 22(11):721-734. PubMed ID: 36301434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease.
    Neys SFH; Rip J; Hendriks RW; Corneth OBJ
    Drugs; 2021 Sep; 81(14):1605-1626. PubMed ID: 34609725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bruton's Tyrosine Kinase, a Component of B Cell Signaling Pathways, Has Multiple Roles in the Pathogenesis of Lupus.
    Satterthwaite AB
    Front Immunol; 2017; 8():1986. PubMed ID: 29403475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bruton's Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
    Lorenzo-Vizcaya A; Fasano S; Isenberg DA
    Immunotargets Ther; 2020; 9():105-110. PubMed ID: 32582577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bruton's tyrosine kinase as a promising therapeutic target for multiple sclerosis.
    Saberi D; Geladaris A; Dybowski S; Weber MS
    Expert Opin Ther Targets; 2023; 27(4-5):347-359. PubMed ID: 37272515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
    Crawford JJ; Johnson AR; Misner DL; Belmont LD; Castanedo G; Choy R; Coraggio M; Dong L; Eigenbrot C; Erickson R; Ghilardi N; Hau J; Katewa A; Kohli PB; Lee W; Lubach JW; McKenzie BS; Ortwine DF; Schutt L; Tay S; Wei B; Reif K; Liu L; Wong H; Young WB
    J Med Chem; 2018 Mar; 61(6):2227-2245. PubMed ID: 29457982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.